Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Casdatifan - Arcus Biosciences

Next Previous
Drug Profile

Casdatifan - Arcus Biosciences

Alternative Names: AB-521; HIF-2a inhibitor - Arcus Biosciences

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcus Biosciences
  • Developer Arcus Biosciences; AstraZeneca
  • Class Alcohols; Antineoplastics; Fluorinated hydrocarbons; Fluorobenzenes; Indenes; Nitriles; Organic sulfur compounds; Small molecules; Sulfides; Tetrahydronaphthalenes
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase I Cancer; Solid tumours
  • No development reported Liver cancer

Most Recent Events

  • 22 Jul 2026 Arcus Biosciences enters in clinical trial collaboration with AVEO Oncology to develop casdatifan in combination with tivozanib for Renal cell carcinoma
  • 22 Jul 2026 Arcus Biosciences enters in clinical trial collaboration with Summit Therapeutics to develop casdatifan in combination with Ivonescimab for Renal cell carcinoma
  • 22 Jul 2026 Arcus Biosciences plans a phase registrational III trial for Renal cell carcinoma (First line therapy) at the end of 2026 (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top